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It has become a mantra in articles and conferences on fertility preserva-
tion: the only option to preserve the fertility of prepubertal girls under-
going gonadotoxic treatment is ovarian tissue cryopreservation (Jadoul
et al., 2010; Revel and Revel-Vilk, 2010; Smitz et al., 2010; Anderson
and Wallace, 2011; Fabbri et al., 2012; Rodriguez-Wallberg and Oktay,
2012; Chung et al., 2013; Mintziori et al., 2014). The ﬁrst healthy live
birth after autotransplantation of ovarian tissue harvested during child-
hood (although not prepubertal) reported in this issue, and thus proof
of principle, is likely to reinforce this dogma even further (Demeestere
et al., 2015). As a consequence, we can expect a growing number of
fertility specialists to be convinced that the offer of cryopreservation
of ovarian tissue to young cancer patients should become standard
practice.
Fortunately, in the case report of the ﬁrst live birth, an important
nuance was added to the ‘only option mantra’: ‘For prepubertal
female patients who face a high risk of treatment-induced POI, the only
option available to preserve fertility is the cryopreservation of ovarian
tissue’ [my emphasis]. For those pediatric patients who have a high risk
of permanent sterility after their cancer treatment, freezing tissue may
indeed be the only way of preserving a chance of future fertility.
However, a cautious approach should be adopted for those patients
whose treatment regimens imply a substantial risk for premature
ovarian failure (POF), but who at the same time have a very small risk
of immediate sterility (patients in the medium- or low-risk categories
in Wallace et al. (2005)). For this group of patients, it is not correct to
say that ovarian tissue cryopreservation (OTC) is their only option of
preserving their fertility and in fact the idea that OTC is the only
option to combat POF is rarely heard in contexts other than that of
oncofertility. Another option, besides the advice not to delay parent-
hood too long, is to bank oocytes once these girls hit puberty if they
turn out to be at risk of POF. From an ethical perspective, there are a
number of reasons to prefer the option of expectant management
combined with oocyte banking over that of OTC.
The advantages of oocyte cryopreservation (OC) after puberty
over OTC before puberty follow from the procedures themselves,
from the timing and often from an interplay between the two.
First of all, it is ethically problematic toperforman invasive surgical pro-
cedurewith unknownbeneﬁts onminorswhocannot give their informed
consent. Any surgical intervention carries a risk of surgical complications,
infections and the risks associatedwith anesthesia.Most physicians avoid
the latter by removing the ovarian tissuewhen the patient is anesthetized
for a different intervention in the treatment of their disease. However,
the other risks remain and are especially worrisome in these patients
as their immune systems are already weakened. Also, many young
cancer patients have low platelet counts, which is another medical risk
factor.
These surgical risks are not the only reason why pediatric oncologists
may be reluctant to adviseOTC for their young patients.While for some
patients cryopreserving ovarian tissue can be perceived as a message of
hope, for others, the prospect of yet another surgical intervention can
cause additional anxiety in both the child and the parents—who are
already overwhelmed by the cancer diagnosis—and thus increase not
only the physical, but also the emotional burden.
For the same reason, as previously noted byWallace et al. (2005), it is
impossible to respectall the conditions foravalid informedconsent at the
point in timewhen it is needed. In the case of minors, one already needs
to relyon informedassent andproxy-consent, but even those aredifﬁcult
to obtain. The intervention often needs to takeplace shortly after receiv-
ing the cancer diagnosis, which, especially in the case of children, is most
disturbing and frightening. Patients and their parents have to digest a
multitude of information, are focused on survival and are terriﬁed of
the prospect of not surviving. They are thus hardly in a good position
to weigh all the pros and cons, especially given the very short time
frame in which this needs to happen.
Next, let us not forget that the preservation and retransplantation of
ovarian tissue from prepubertal girls remains an experimental proced-
ure. Although at least 35 live births have been reported following the
transplantation of ovarian tissue from adult patients (Demeestere
et al., 2015), uncertainties linger about how the prepubertal tissue will
respond when transplanted into an adult woman and about the extent
to which the small amounts of tissue available in young girls are a limiting
factor for successful treatment. Moreover, the fact that these children
have only one ovary left is a concern in itself. If anything happens to the
remaining functional ovary (cyst, torsion. . .), the patient ends upwith iat-
rogenic infertility. Another major concern is that autologous transplant-
ation involves a risk of transplanting malignant cells back to the patient.
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In vitro maturation may be a way to avoid this risk, but is not possible at
this time.
Finally, especially for the category of patients that we are concerned
with here (low to medium risk), there is a considerable chance that
ovarian tissue that is frozen at the timeof treatmentwill never be retrans-
planted.Theremaybe anumberof reasons for this. Firstof all, thepatient
maystill be fertilewhen shewants to reproduceor her subfertilitymaybe
adequately addressed with standard assisted reproductive techniques.
As shown in a study by Brougham et al. (2012), whereas anti-Mullerian
hormone (AMH) levels fell to undetectable concentrations in all girls
that were classiﬁed as high-risk and did not recover, AMH levels did
recover signiﬁcantly in the medium- and low-risk groups. Another
study by Wallace et al. (2014) demonstrated that the ‘Edinburgh selec-
tion criteria’ (criteria for who is a good candidate for fertility preserva-
tion) are very efﬁcient at selecting those young cancer patients who
are truly at risk of losing their fertility (only 8%!) and at identifying
thosewho are not. Moreover, even in the high-risk group, some patients
may never desire to embark on parenthood or never ﬁnd themselves in
the right circumstances to do so (which cannot be predicted at a young
age), some patients’ fertility may be compromised by radiation damage
to the uterus or some may not have survived their illness. In all of
these cases, wewill have submitted a young cancer patient to an invasive
procedure without any beneﬁt.
If, insteadof freezing ovarian tissue at the timeof cancer treatment,we
would advise these low to medium-risk girls and their parents to come
back to the clinic at age 18 years for an ovarian reserve assessment so
that they might still bank oocytes if needed, what would the picture
look like then?
With respect to the risks involved, although ovarian stimulation and
oocyte retrieval are not risk-free procedures and involve discomfort as
well, these interventions are considerably less invasive than the
removal of an ovary. The most prominent risk of ovarian stimulation—
ovarian hyperstimulation syndrome—has virtually become a risk of the
past thanks to the widespread adoption of new stimulation protocols
which are especially indicated when all oocytes are frozen (Devroey
et al., 2011). The next step of the procedure—oocyte vitriﬁcation—
is increasingly considered to be an established procedure, although
uncertainties about possible long-term effects remain. In any case, it is
fair to say that OC is less experimental than OTC, especially when
comparing OC for adults with OTC for minors.
Regarding informed consent, the decision to cryopreserve oocytes
can nowbe taken by the patient herself, instead of by her parents. More-
over, it can be taken in a more ‘relaxed’ atmosphere. The patient’s life is
not in immediate danger anymore, she has the time to gather and digest
all relevant information and time to consider whether or not oocyte
cryopreservation is something she desires to pursue.
There are, however, also a number of possible risks associated with
relinquishing the chance of cryopreserving ovarian tissue before treat-
ment. In a number of cases, the prediction of the impact of the treatment
on the ovarian reservewill bewrong. Some patients, despite starting out
in a low-ormedium-risk category,will nevertheless end up sterile oronly
have bad quality oocytes left at age 18 years. Also, an important aspect
that remains to be investigated is whether or not a diminished ovarian
reserve caused by gonadotoxic treatments should be interpreted in
the same way as a diminished ovarian reserve related to aging. If it
turns out that these patients have less oocytes, but that the ones they
have are of excellent quality (as opposed to reproductively speaking
older women), then it may be possible to bank good quality oocytes at
puberty. If however, not only the quantity but also the quality of
oocytes that these women have left is severely affected, their prospects
will be bleaker. Another downside to postponement of the decision to
preserve fertility is that once the patient has left the clinic, she may
never return. Once a patient has survived cancer, the associated fertility
problems may vanish in the background until she attempts to establish a
pregnancy, at which point it may be too late to intervene. This may par-
ticularly be the case as the original decision to postpone fertility preser-
vation will oftentimes be taken by the parents, rather than by the child
herself. Ideally, these young women should get a ‘friendly reminder’
when they reach puberty. Relying on gynecologists to deliver this
message is probably not very effective, as not all adolescents visit gyne-
cologists and many of those who do might fail to inform their gynecolo-
gists about the fact that they are childhood cancer survivors. The
oncologist is therefore probably better placed, on the condition that
the patient still visits the oncologist for regular check-ups.
In conclusion, the ﬁrst healthy live birth after ovarian tissue freezing in
childhood is a great achievement andhopefully this procedurewill be able
to safeguard the fertility of young cancer patients who would otherwise
be left sterile after their cancer treatment. However, some restraint in
portraying this option as young girls’ only option is in order. Whereas
this is the truth for those girls at a high risk of sterility, it is not for a signiﬁ-
cant group of patients who have a low tomedium risk of infertility before
reaching reproductive age. For this group, the ruling paradigm that they
can either choose to cryopreserve prepubertal ovarian tissue with no
guarantee of future beneﬁt or do nothing and hope that they will still
be fertile by the time they want to reproduce, is incomplete. A possible
third option that should be included and presented to young patients, is
the possibility to come back to the clinic once they reach adolescence,
test their ovarian reserve and if needed and desired, cryopreserve
oocytes (or ovarian tissue for that matter) at that time. For sure, the
ethical superiority of this third option will depend on the clinical out-
comes of both procedures, which are both uncertain at this time. Yet,
the sheer absence of this third option in the existing literature on fertility
preservationoptions, and thusprobably also in thepossibilities offered to
patients, is remarkable and needs to be addressed.
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